Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2Breast Neoplasms 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Overweight 1Osteoradionecrosis 1Obesity 1Neoplasms 1Mouth Neoplasms 1Metastasising Cancer of Unknown Primary 1Invasive Breast Cancer 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Digestive System Neuroendocrine Tumor G1 1Coronary Artery Disease 1Colorectal Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Metformin 2sultamicillin 1semaglutide 1Ursodeoxycholic Acid 1Tirzepatide 1Resistance Training 1Propofol 1Progestins 1Nutrition Assessment 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Magnetic Resonance Spectroscopy 1Hysteroscopy 1Exercise 1Exenatide 1Estrogen Replacement Therapy 1Docosahexaenoic Acids 1Cyproterone 1(2-(1R)-1-cyclopropyl)ethyl-6-isopropyl-phenol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Overweight × Magnetic Resonance Spectroscopy × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡